Roivant Sciences Ltd. $ROIV Shares Sold by Capricorn Fund Managers Ltd

Key Points

• Capricorn Fund Managers Ltd slashed its Roivant Sciences stake by 95.5% in the first quarter, selling 425,500 shares and leaving it with 20,000 shares worth about $554,000.
• Roivant Sciences shares were up 1.9% to $35.39, near their 52-week high of $35.90, after the company recently reported quarterly EPS of $0.28, beating analyst expectations.
• Insider selling has been heavy: CEO Eric Venker and Director Daniel Allen Gold sold a combined 1 million shares in late June, while analysts still largely rate the stock a Moderate Buy with a consensus target price of $33.59.

Capricorn Fund Managers Ltd lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 95.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,000 shares of the company's stock after selling 425,500 shares during the quarter. Capricorn Fund Managers Ltd's holdings in Roivant Sciences were worth $554,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Peak Financial Advisors LLC acquired a new stake in Roivant Sciences during the 1st quarter worth approximately $2,933,000. Pictet Asset Management Holding SA raised its stake in shares of Roivant Sciences by 15.6% during the first quarter. Pictet Asset Management Holding SA now owns 2,673,233 shares of the company's stock worth $74,049,000 after purchasing an additional 360,797 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of Roivant Sciences during the first quarter worth $3,620,000. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Roivant Sciences by 4.6% during the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after purchasing an additional 445 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in Roivant Sciences by 2.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 7,076,488 shares of the company's stock valued at $196,019,000 after buying an additional 139,376 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Trading Up 1.9%

ROIV stock opened at $35.39 on Wednesday. The company has a market cap of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13. Roivant Sciences Ltd. has a 52 week low of $10.70 and a 52 week high of $35.90. The company's 50-day moving average price is $29.88 and its 200 day moving average price is $27.02.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to analysts' expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period last year, the company posted ($0.29) earnings per share. On average, equities research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business's stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the completion of the sale, the director directly owned 13,701,546 shares in the company, valued at approximately $473,388,414.30. The trade was a 5.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 2,341,475 shares of company stock valued at $76,791,271. Company insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ROIV. Weiss Ratings cut shares of Roivant Sciences from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, May 22nd. Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a report on Friday, March 20th. They set an "outperform" rating and a $35.00 price target for the company. Citigroup raised their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, May 21st. Leerink Partners set a $42.00 target price on Roivant Sciences in a research report on Thursday, May 21st. Finally, TD Cowen increased their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a "buy" rating in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.